Post-DCAT Week 2026: The Pharma Trends That Are Already Reshaping CDMO, CRO and Biotech Hiring

Every March, the global bio/pharmaceutical industry converges on New York City for DCAT Week. Hosted by the Drug, Chemical and Associated Technologies Association, it's the event where senior leaders across CDMOs, CROs, biotech companies, and drug manufacturers get into the room together for a week of meetings, strategic conversations, and deal-making. What gets said there tends to set the tone for the year ahead.

DCAT Week 2026 was no different. Six weeks on, the themes that dominated those conversations aren't just holding up. They're accelerating. For companies operating in the CDMO, CRO, and biotech space, and for the talent professionals who support them, understanding those trends isn't optional. It's the difference between being prepared for what's coming and being caught short by it.

‍

Supply Chains Can't Be Static Anymore

The most consistent theme coming out of DCAT Week 2026 was the end of the static supply chain. Recent global disruptions, the COVID-19 pandemic, shifting geopolitical tensions, and a US policy environment increasingly hostile to pharmaceutical imports have together exposed just how fragile purely efficiency-driven supply chains actually are.

The conversation at DCAT Week wasn't about whether pharma supply chains needed to change. That debate is settled. It was about how fast companies could adapt, and what it would cost them to do it.

CDMOs with multi-site, multi-region footprints were the ones fielding the most interest. The ability to pivot production between US and European facilities, to offer what the industry has started calling "local-for-local" manufacturing, has shifted from a nice-to-have to a genuine competitive differentiator. Companies like ESTEVE CDMO, Siegfried, Recipharm, and Fujifilm Diosynth Biotechnologies were all communicating the same message at DCAT Week: geographic redundancy is now core to value proposition, not peripheral to it.

Six weeks later, that positioning looks prescient. The continued pressure of US tariff policy on pharmaceutical imports has made supply chain resilience a board-level conversation across the sector. Companies that can offer sponsors the confidence of regional manufacturing continuity are in a strong position. Those that can't are re-evaluating their infrastructure rapidly.

‍

Reshoring Is Creating a Talent Crisis in Slow Motion

The US reshoring movement in pharma is generating extraordinary levels of capital investment. Since early 2025, major pharmaceutical companies have pledged more than $480 billion toward US manufacturing expansion, with announcements from Eli Lilly, Johnson and Johnson, Merck, and others accounting for much of that total. The establishment of 22 new manufacturing sites is expected to create approximately 44,000 new jobs.

That sounds like good news. For pharma talent professionals, it's also a warning.

The US life sciences talent pool is already stretched. Building and operating complex, highly regulated biopharmaceutical manufacturing facilities requires professionals who don't just have relevant qualifications but have years of hands-on experience navigating GMP environments, regulatory inspections, and the demands of commercial-scale production. Those professionals exist, but many of them are currently employed in European manufacturing hubs or clustered in established US centres like Boston-Cambridge, New Jersey, and San Diego.

The new facilities being announced aren't all going up in those locations. That mismatch between where talent is and where capacity is being built creates serious workforce planning challenges that companies are only beginning to grapple with.

For CDMOs in particular, this pressure is sharpest. They're being asked to expand their own US operations to support sponsors who need reshored manufacturing, at the same time as those sponsors are competing for the same pool of experienced professionals. The limiting factor in this reshoring boom may not be regulatory timelines or capital availability. It's likely to be talent.

‍

Specialised Capabilities Are Becoming Bottlenecks

A second major trend that surfaced at DCAT Week 2026, and has only grown in significance since, is the pressure on specialised manufacturing capabilities. As pharmaceutical pipelines continue to shift toward more complex modalities, including highly potent APIs (HPAPIs), advanced drug delivery systems, bioconjugates, and cell and gene therapies, the demand for specialist technical expertise is rising faster than the available capacity to provide it.

CDMOs that want to compete for the most valuable outsourcing contracts need to invest ahead of demand in both facilities and people. That's capital-intensive and requires a clear read on where the pipeline is heading. The companies that made those investments early are now well positioned. Those that didn't are facing a difficult catch-up.

Small molecules remain a significant part of the picture. They account for more than half of all molecules currently in clinical development, and the segment has gained renewed momentum following the FDA approval of an oral GLP-1 therapy in late 2025. For CDMOs with strong small molecule API capabilities, particularly in HPAPI and complex solid dosage, the demand environment heading into the second half of 2026 looks strong.

Across modalities, the pattern is consistent: sponsors are moving away from purely transactional CDMO relationships toward longer-term partnerships with organisations that have proven regulatory track records and genuine technical depth. That shift rewards CDMOs that have invested in their people and capabilities over time, rather than those positioning purely on cost or speed.

‍

‍

The Digital Capability Gap Is Widening

A third trend discussed at DCAT Week 2026, and increasingly visible across the CDMO and biotech landscape since, is the growing importance of digital readiness. Artificial intelligence and advanced analytics are no longer peripheral to life sciences operations. They're being embedded into core functions across clinical operations, regulatory affairs, pharmacovigilance, and manufacturing quality systems.

Research shared at the event indicated that around 92% of CDMOs report that sponsors now raise digital capability requirements during commercial negotiations. The gap between those with genuine digital integration and those still operating on legacy systems is becoming a market differentiator.

For hiring, this creates a specific and persistent challenge. The professionals most in demand are those who combine deep domain knowledge in areas like regulatory affairs, quality assurance, or bioprocess engineering with sufficient data literacy to work within increasingly automated environments. These hybrid profiles are in short supply across the sector.

This isn't a future trend. It's shaping hiring decisions right now across CDMOs, CROs, and growth-stage biotech companies alike.

‍

What This Means for CDMO, CRO and Biotech Talent in 2026

The themes from DCAT Week 2026 converge on a single, significant conclusion for talent: the second half of 2026 is going to be a demanding hiring environment for life sciences organisations, and a competitive one for the right candidates.

For companies in the CDMO, CRO, and biotech space, workforce planning needs to move faster than it has historically. The organisations that are going to secure the talent they need, whether that's experienced biomanufacturing engineers to support US capacity expansion, specialist chemists for HPAPI programmes, regulatory professionals with digital fluency, or senior commercial leaders capable of building strategic CDMO partnerships, are those that start those conversations early.

Waiting until a role is open, writing a job description, and hoping the right candidate appears isn't a viable strategy in this market. Life sciences unemployment sits below 2%. The most experienced professionals in high-demand functions are rarely actively looking. And the competition for them is, in many cases, coming from companies with $27 billion investment programmes behind them.

At Vector Talent, we work exclusively within the CDMO, CRO, and biotech sectors. The trends that dominated DCAT Week 2026 are the same conversations we're having with our clients and candidates every day. Supply chain restructuring, specialised capability investment, digital transformation, and the talent bottlenecks sitting underneath all of it. We understand the landscape, the organisations shaping it, and the professionals who can navigate it.

If those conversations are relevant to your organisation's plans for 2026 and beyond, we'd welcome the opportunity to talk.